Displaying 81 - 100 of 350
Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Date
By
Rebecca Kelly Slaughter, Former Commissioner
Matter Number
P221201
FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs
Date
The Federal Trade Commission announced that it will ramp up enforcement against any illegal bribes and rebate schemes that block patients’ access to competing lower-cost drugs. The enforcement policy...
Public Statement
Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022
Date
Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Date
By
Alvaro Bedoya, Former Commissioner
Matter Number
P221201
FTC and Justice Department to Hold Two-Day Virtual Public Workshop Starting Tomorrow that Re-examines Antitrust Enforcement in the Pharmaceutical Industry
Date
The Federal Trade Commission and the U.S. Department of Justice (DOJ) will host a two-day workshop starting tomorrow, that explores new approaches to enforcing the antitrust laws in the pharmaceutical...
Statement of Chair Lina M. Khan Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Lina M. Khan, Former Chair and Commissioner
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Noah Joshua Phillips, Former Commissioner;
Christine S. Wilson, Former Commissioner
Matter Number
P221200
FTC Launches Inquiry Into Prescription Drug Middlemen Industry
Date
The Federal Trade Commission announced today that it will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to provide information...
FTC and Justice Department to Hold Two-Day Virtual Public Workshop Examining Antitrust Enforcement in the Pharmaceutical Industry
Date
The Federal Trade Commission and the U.S. Department of Justice (DOJ) will host a two-day workshop to explore new approaches to enforcing the antitrust laws in the pharmaceutical industry. The...
Federal Register Notice
Hikma Pharmaceuticals PLC/Custopharm, Inc.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Date
Public Statement
Remarks of Chair Lina M. Khan Regarding the 6(b) Study on Pharmacy Benefit Managers
Date
Matter Number
P221002
File
Text of Statement
(195.96 KB)
Statement of Chair Lina M. Khan on the Ruling by Judge Denise L. Cote Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al
Date
Today, U.S. District Court Judge Denise Cote held “Pharma Bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission and a group of seven state enforcers. Finding that...
ANI/Novitium, In the Matter of
The Federal Trade Commission required generic drug marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to divest, to Prasco LLC, ANI’s development rights to one generic drug and assets with respect to another generic drug as part of a settlement resolving charges that ANI’s $210 million acquisition of Novitium likely would be anticompetitive. According to the complaint, without a remedy, the acquisition would likely harm future competition in U.S. markets for both of these generic products. The order requires ANI and Novitium to divest ANI’s rights and assets to generic SMX-TMP oral suspension and generic dexamethasone tablets to Prasco within 10 days after the acquisition is final. On Jan. 12, 2022, the Commission announced the final consent order in this matter.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
211 0101
Docket Number
C-4754
Case Status
Pending
Displaying 81 - 100 of 350